金迪克(688670) - 2024 Q4 - 年度业绩预告

Financial Projections - The company expects 2024 annual revenue to be between 80 million and 90 million CNY, a decrease of 44.59 million to 54.59 million CNY from the previous year, representing a year-on-year decline of 33.13% to 40.56%[3] - The projected net profit attributable to the parent company for 2024 is expected to be between -100 million and -90 million CNY, a decrease of 19.0097 million to 29.0097 million CNY from the previous year, reflecting a year-on-year decline of 26.78% to 40.86%[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between -110 million and -100 million CNY, a decrease of 27.4291 million to 37.4291 million CNY from the previous year, indicating a year-on-year decline of 37.80% to 51.58%[3] Vaccine Production and Development - The company plans to accelerate the production, approval, and sales of influenza vaccines in 2025 to capture market opportunities for the 2025-2026 flu season[8] - A new workshop for influenza vaccine production is under construction, with multiple production lines expected to be operational by April 2026, which will enhance capacity and shorten production cycles[8] - The company is focusing on expanding its vaccine product line, particularly in the influenza vaccine sector, with a current vaccination rate in China around 3%, significantly lower than the nearly 50% rate in Europe and the US[11] - The company is committed to enhancing its research and development efforts, with a significant increase in R&D investment compared to the previous year[12] Revenue Impact and Challenges - The company has adjusted the prices of its quadrivalent influenza vaccines, which has negatively impacted current revenue[9] - The company anticipates a total asset impairment provision of approximately 24.0325 million CNY for unsellable influenza vaccines due to their approaching expiration[9] Sales Network - The company has established a sales network covering over 2,000 district and county-level disease control centers across the country[13]